A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated Plasmodium falciparum Treatment in Pregnancy
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To date no comparative trials have been done, to our knowledge, of fixed-dose artemisinin combination therapies (ACTs) for the treatment of Plasmodium falciparum malaria in pregnancy. Evidence on the safety and efficacy of ACTs in pregnancy is needed as these drugs are being used increasingly throughout the malaria-affected world. The objective of this study was to compare the efficacy, tolerability, and safety of artemether-lumefantrine, the most widely used fixed ACT, with 7 d artesunate monotherapy in the second and third trimesters of pregnancy. METHODS AND FINDINGS: An open-label randomised controlled trial comparing directly observed treatment with artemether-lumefantrine 3 d (AL) or artesunate monotherapy 7 d (AS7) was conducted in Karen women in the border area of northwestern Thailand who had uncomplicated P. falciparum malaria in the second and third trimesters of pregnancy. The primary endpoint was efficacy defined as the P. falciparum PCR-adjusted cure rates assessed at delivery or by day 42 if this occurred later than delivery, as estimated by Kaplan-Meier survival analysis. Infants were assessed at birth and followed until 1 y of life. Blood sampling was performed to characterise the pharmacokinetics of lumefantrine in pregnancy. Both regimens were very well tolerated. The cure rates (95% confidence interval) for the intention to treat (ITT) population were: AS7 89.2% (82.3%-96.1%) and AL 82.0% (74.8%-89.3%), p = 0.054 (ITT); and AS7 89.7% (82.6%-96.8%) and AL 81.2% (73.6%-88.8%), p = 0.031 (per-protocol population). One-third of the PCR-confirmed recrudescent cases occurred after 42 d of follow-up. Birth outcomes and infant (up to age 1 y) outcomes did not differ significantly between the two groups. The pharmacokinetic study indicated that low concentrations of artemether and lumefantrine were the main contributors to the poor efficacy of AL. CONCLUSION: The current standard six-dose artemether-lumefantrine regimen was well tolerated and safe in pregnant Karen women with uncomplicated falciparum malaria, but efficacy was inferior to 7 d artesunate monotherapy and was unsatisfactory for general deployment in this geographic area. Reduced efficacy probably results from low drug concentrations in later pregnancy. A longer or more frequent AL dose regimen may be needed to treat pregnant women effectively and should now be evaluated. Parasitological endpoints in clinical trials of any antimalarial drug treatment in pregnancy should be extended to delivery or day 42 if it comes later. TRIAL REGISTRATION: Current Controlled Trials ISRCTN86353884.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of artesunate in early pregnancy has not led to any additional toxic effects [135, 136].”
From Current update on malaria in pregnancy: a systematic review (2025) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in Thailand the cure rate at day 42 was only 82%,138 possibly due to the low day 7 lumefantrine concentrations.”
From Malaria in pregnancy. (2013) · cites this paper as [138]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“AL was safe and well tolerated.136–138”
From Malaria in pregnancy. (2013) · cites this paper as [138]
In the citing paper
“However, application of highly sensitive molecular techniques confirmed that the frequency of low level (submicroscopic) infections is higher than expected in all endemic regions [16,17].”
From Submicroscopic infection of placenta by Plasmodium produces Th1/Th2 cytokine imbalance, inflammation and hypoxia in women from north-west Colombia (2014) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical assessment of gestational age in the newborn infant
Dubowitz, L. M. S., Dubowitz, V., & Goldberg, C. (1970) · The Journal of Pediatrics · doi:10.1016/s0022-3476(70)80038-5 · Cited by 2,241
Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number
Price, R. N., Uhlemann, A.-C., Brockman, A., McGready, R., Ashley, E., Phaipun, L., Patel, R., Laing, K., Looareesuwan, S., White, N. J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16767-6 · Cited by 853 · cited 1×
“Resistance is associated with an increase in Pfmdr1 copy numbers [33–35].”
BackgroundSelf-citationClinical Pharmacokinetics and Pharmacodynamics of Artemether-Lumefantrine
White, N. J., van Vugt, M., & Ezzet, F. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937020-00002 · Cited by 351
Self-citationPrice, R. N., Uhlemann, A.-C., van Vugt, M., Brockman, A., Hutagalung, R., Nair, S., Nash, D., Singhasivanon, P., Anderson, T. J. C., Krishna, S., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/503423 · Cited by 317 · cited 1×
“Parasites with increased Pfmdr1 copy number are also slightly less sensitive to artemisinin derivatives, although the differences are much less than for lumefantrine [36].”
BackgroundSelf-citationMalaria during pregnancy in an area of unstable endemicity.
Nosten, F., ter Kuile, F., Maelankirri, L., Decludt, B., & White, N. J. (1991) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(91)90205-d · Cited by 294 · cited 1×
“The ANCs provided early detection and treatment of malaria and reduced both morbidity and mortality [3].”
BackgroundSelf-citationEyes on the present and looking into the future
Piva, J. P., & Garcia, P. C. R. (2001) · Jornal de Pediatria · doi:10.2223/jped.98 · Cited by 279
Price, R. N., Cassar, C., Brockman, A., Duraisingh, M., van Vugt, M., White, N. J., Nosten, F., & Krishna, S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.12.2943 · Cited by 279 · cited 1×
“Resistance is associated with an increase in Pfmdr1 copy numbers [33–35].”
BackgroundSelf-citationGuyatt, H., & Snow, R. (2001) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2001.64.36 · Cited by 252 · cited 2×
“The newborn anthropometric results and neurological scores (Table 5) were very similar in the two groups and are consistent with having multiple malaria infections in pregnancy [18,43,45,46].”
BackgroundResultVugt, M. V., Wilairatana, P., Gemperli, B., Gathmann, I., Phaipun, L., Brockman, A., Luxemburger, C., White, N. J., Nosten, F., & Looareesuwan, S. (1999) · The American journal of tropical medicine and hygiene · doi:10.4269/ajtmh.1999.60.936 · Cited by 194
Self-citationBrockman, A., Price, R. N., van Vugt, M., Heppner, D. G., Walsh, D., Sookto, P., Wimonwattrawatee, T., Looareesuwan, S., White, N. J., & Nosten, F. (2000) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(00)90080-4 · Cited by 185 · cited 1×
“), but the exploratory analysis shows a clear superiority of AS7 over AL in this particular subgroup. There was no difference in efficacy between AL and AS7 in the treatment of primary or new infections. This difference between primary and recrudescent infections presumably reflects reduced class susceptibility of the…”
Self-citation
Cited by
WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group (2015) · BMC Medicine · doi:10.1186/s12916-015-0456-7 · Cited by 464
Malaria in pregnancy in the Asia-Pacific region
Rijken, M. J., McGready, R., Boel, M. E., Poespoprodjo, R., Singh, N., Syafruddin, D., Rogerson, S., & Nosten, F. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70315-2 · Cited by 181
Self-citationTakem, E. N., & D'Alessandro, U. (2013) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2013.010 · Cited by 185
“pyrimethamine; PF=parasitological failure; CR=clearance/cure rate; PE=parasitological efficacy; PK=pharmacokinetics; PNG=Papua New Guinea; *supervised quinine for 7 days; a peripheral microscopy, placental microscopy and placental histology; ‡ part of data in McGready 2001 [118], Mc Gready 2002 [149]; b data from McGr…”
BackgroundKajubi, R., Ochieng, T., Kakuru, A., Jagannathan, P., Nakalembe, M., Ruel, T., Opira, B., Ochokoru, H., Ategeka, J., Nayebare, P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32224-4 · Cited by 136
Drug-Resistant Malaria: The Era of ACT
Lin, J. T., Juliano, J. J., & Wongsrichanalai, C. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0099-y · Cited by 121
“There is increasing evidence that AL is safe in the second and third trimesters of pregnancy, though a longer course of treatment may be needed because of lower achieved plasma concentrations of artemether, dihydroartemisinin (DHA), and lumefantrine [ 32 ].”
BackgroundClark, R. L. (2009) · Reproductive Toxicology · doi:10.1016/j.reprotox.2009.05.002 · Cited by 124
Muehlenbachs, A., Fried, M., McGready, R., Harrington, W. E., Mutabingwa, T. K., Nosten, F., & Duffy, P. E. (2010) · The Journal of Infectious Diseases · doi:10.1086/656723 · Cited by 100
“falciparum and Plasmodium vivax) detected and treated during pregnancy [26].”
Self-citationFour Artemisinin-Based Treatments in African Pregnant Women with Malaria
The PREGACT Study Group (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508606 · Cited by 99
Piola, P., Nabasumba, C., Turyakira, E., Dhorda, M., Lindegardh, N., Nyehangane, D., Snounou, G., Ashley, E. A., McGready, R., Nosten, F., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70202-4 · Cited by 99
Self-citationTarning, J., McGready, R., Lindegardh, N., Ashley, E. A., Pimanpanarak, M., Kamanikom, B., Annerberg, A., Day, N. P. J., Stepniewska, K., Singhasivanon, P., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00195-09 · Cited by 99
“out by a physician and the results were recorded, as described previously (34).”
BackgroundMethodSelf-citationClinical Pharmacology During Pregnancy
(2013) · Elsevier eBooks · doi:10.1016/c2010-0-67194-x · Cited by 90
Obstetric Pharmacokinetic Dosing Studies are Urgently Needed
McCormack, S. A., & Best, B. M. (2014) · Frontiers in Pediatrics · doi:10.3389/fped.2014.00009 · Cited by 86
Arthropod borne disease: the leading cause of fever in pregnancy on the Thai-Burmese border.
McGready, R., Ashley, E. A., Wuthiekanun, V., Tan, S. O., Pimanpanarak, M., Viladpai-nguen, S. J., Jesadapanpong, W., Blacksell, S. D., Peacock, S. J., Paris, D. H., et al. (2010) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000888 · Cited by 78
“falciparum malaria in the 2 or 3 trimester of pregnancy were enrolled into a treatment study reported elsewhere [6].”
MethodSelf-citationRijken, M. J., McGready, R., Phyo, A. P., Lindegardh, N., Tarning, J., Laochan, N., Than, H. H., Mu, O., Win, A. K., Singhasivanon, P., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05067-11 · Cited by 75
“Inferior cure rates in treating recrudescent infections in pregnant women have been reported before (16).”
BackgroundSelf-citationMalaria: past, present, and future
Li, Q., Liu, T., Lv, K., Liao, F., Wang, J., Tu, Y., & Chen, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02246-3 · Cited by 103
Malaria: an update on current chemotherapy
Visser, B. J., van Vugt, M., & Grobusch, M. P. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.944499 · Cited by 81
“DHA-PIP was highly effective in women with uncomplicated P. falciparum malaria in Thailand [173,174].”
BackgroundResultInfluentialManyando, C., Mkandawire, R., Puma, L., Sinkala, M., Mpabalwani, E., Njunju, E., Gomes, M., Ribeiro, I., Walter, V., Virtanen, M., et al. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-249 · Cited by 67
“exposure in the second and third trimesters [6-11], and the scarcity of data on first trimester exposure versus the risk of embryotoxicity or death [7,12,13].”
BackgroundChaikitgosiyakul, S., Rijken, M. J., Muehlenbachs, A., Lee, S. J., Chaisri, U., Viriyavejakul, P., Turner, G. D., Pongponratn, E., Nosten, F., & McGready, R. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-4 · Cited by 66
“Ethical permission for collection of placental biopsies in the specific studies was granted with each separate study [17-21].”
BackgroundInfluentialSelf-citationTreating Severe Malaria in Pregnancy: A Review of the Evidence
Kovacs, S. D., Rijken, M. J., & Stergachis, A. (2015) · Drug Safety · doi:10.1007/s40264-014-0261-9 · Cited by 66
“Artesunate is associated with higher cure rates, lower gametocyte carriage, and lower treatment failure than quinine-based therapies for the treatment of uncomplicated malaria in pregnancy [69, 70, 72, 83, 84].”
BackgroundManyando, C., Kayentao, K., D’Alessandro, U., Okafor, H. U., Juma, E., & Hamed, K. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-141 · Cited by 62
McGready, R. M., Prakash, J. A. J., Benjamin, S., Watthanaworawit, W., Anantatat, T., Tanganuchitcharnchai, A., Ling, C. L., Tan, S. O., Ashley, E. A., Pimanpanarak, M., et al. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003327 · Cited by 65
“Most treatment efficacy studies of typhus have been limited to a short follow-up of 28 days but like malaria [47] a longer duration of follow-up is likely to be required to monitor for relapse in pregnant women and further pharmacokinetic studies are required [48].”
BackgroundSelf-citationSaito, M., Briand, V., Min, A. M., & McGready, R. (2020) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(20)30099-7 · Cited by 61
Self-citationAntimalarial drugs for treating and preventing malaria in pregnant and lactating women
Saito, M., Gilder, M. E., McGready, R. M., & Nosten, F. H. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1535593 · Cited by 58
“In another two RCTs including 250 patients in total, the prevalence of miscarriage, stillbirth, preterm, low birth weight and congenital abnormality after AL were not different from those after quinine [12] or artesunate monotherapy [48].”
BackgroundInfluentialSelf-citationKredo, T., Mauff, K. A. L., der Walt, J. S. V., Wiesner, L., Maartens, G., Cohen, K., Smith, P. J., & Barnes, K. I. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05265-11 · Cited by 59
“Various therapeutic thresholds have been reported for the day 7 lumefantrine concentration, ranging between 175 and 500 ng/ml, depending on the prevalence of resistance and the method used for determining this threshold; of these, 280 ng/ml is the most widely cited (3, 12, 13, 23, 27, 28, 41).”
BackgroundMethodMcGready, R., White, N., & Nosten, F. (2011) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2010.02810.x · Cited by 54
Self-citationCurrent knowledge and challenges of antimalarial drugs for treatment and prevention in pregnancy
Sevene, E., González, R., & Menéndez, C. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003733599 · Cited by 66
“AL was well tolerated and safe in a study conducted in Thailand among 125 pregnant women [77,78].”
BackgroundKloprogge, F., Piola, P., Dhorda, M., Muwanga, S., Turyakira, E., Apinan, S., Lindegårdh, N., Nosten, F. H., Day, N., White, N. J., et al. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.59 · Cited by 53
Self-citationHuang, L., Parikh, S., Rosenthal, P. J., Lizak, P. S., Marzan, F., Dorsey, G., Havlir, D. V., & Aweeka, F. T. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31826ebb5c · Cited by 54
“However, for patients within whom pharmacokinetic (PK) exposure to AL may be reduced (eg, in the context of enzyme inducers or pregnancy), recrudescence rates may increase and in the context of pregnancy have been reported to be higher.(14) ACT pharmacology is complex, and significant drug–drug interactions with ART,…”
BackgroundCurrent update on malaria in pregnancy: a systematic review
Minwuyelet, A., Yewhalaw, D., Siferih, M., & Atenafu, G. (2025) · Tropical Diseases, Travel Medicine and Vaccines · doi:10.1186/s40794-025-00248-1 · Cited by 49
Tärning, J., Kloprogge, F., Dhorda, M., Jullien, V., Nosten, F. H., White, N. J., Guerin, P. J., & Piola, P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00683-13 · Cited by 49
“in Thailand receiving artemether-lumefantrine (40).”
Self-citationMutagonda, R. F., Kamuhabwa, A. A. R., Minzi, O., Massawe, S. N., Asghar, M., Homann, M. V., Färnert, A., & Aklillu, E. (2017) · Malaria Journal · doi:10.1186/s12936-017-1914-9 · Cited by 46
“The study participants received six doses of four tablets of ALu (Coartem®; Novartis Pharma AG, Basel, Switzerland) (20 mg artemether and 120 mg lumefantrine) over the course of 3 days at 0, 8, 24, 36, 48, and 60 h.”
BackgroundInfluentialTreatment of uncomplicated and severe malaria during pregnancy
D’Alessandro, U., Hill, J., Tärning, J., Pell, C. L., Webster, J., Gutman, J., & Sevene, E. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30065-3 · Cited by 51
The Use of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium vivax Malaria
Bassat, Q. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001325 · Cited by 44
“This includes the most extensive data for any ACT in children and pregnant women [40–44], the two populations most vulnerable to malaria.”
BackgroundMosha, D., Guidi, M., Mwingira, F., Abdulla, S., Mercier, T., Decosterd, L. A., Csajka, C., & Genton, B. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02595-14 · Cited by 43
“It is also higher than the concentrations previously reported in nonpregnant adults and pediatric patients in Tanzania Ifakara), Thailand, Cambodia, and the Lao People’s Democratic Republic (22, 24, 45, 46).”
BackgroundResultInfluentialHoglund, R. M., Adam, I., Hanpithakpong, W., Ashton, M., Lindegårdh, N., Day, N., White, N. J., Nosten, F. H., & Tärning, J. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-398 · Cited by 46
Self-citationTarning, J., Kloprogge, F., Piola, P., Dhorda, M., Muwanga, S., Turyakira, E., Nuengchamnong, N., Nosten, F., Day, N. P., White, N. J., et al. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-293 · Cited by 43
Self-citationTripathi, C. B., Beg, S., Kaur, R., Shukla, G., Bandopadhyay, S., & Singh, B. (2016) · Drug Delivery · doi:10.3109/10717544.2016.1162876 · Cited by 39
“The observed results are in consonance with literature showing increased efficacy of artemether when administered in nanoformulations (McGready et al., 2008; Cachet et al., 2009).”
ResultSaito, M., Mansoor, R., Kennon, K., Anvikar, A. R., Ashley, E. A., Chandramohan, D., Cohee, L. M., D'Alessandro, U., Genton, B., Gilder, M. E., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30064-5 · Cited by 39
Self-citationAli, S., Najmi, M. H., Tärning, J., & Lindegårdh, N. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-275 · Cited by 45
“Recent reports have shown lower cure rates in pregnant women with uncomplicated falciparum malaria due to lower drug concentrations of artemether, dihydroartemisinin and lumefantrine [10-12].”
ResultAgudelo, O. M., Aristizabal, B. H., Yanow, S. K., Arango, E., Carmona-Fonseca, J., & Maestre, A. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-122 · Cited by 37
Li, Q., & Weina, P. J. (2009) · Molecules · doi:10.3390/molecules15010040 · Cited by 43
“[39] [40] [41] [42] [43] [44] [2] [45] [46] [47]”
Muehlenbachs, A., Nabasumba, C., McGready, R., Turyakira, E., Tumwebaze, B., Dhorda, M., Nyehangane, D., Nalusaji, A., Nosten, F., Guerin, P. J., et al. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-150 · Cited by 35
“The efficacy of artesunate and artemisinin-based combination therapy (ACT) in pregnancy has been well documented in Asia [5-8], however data on efficacy of ACT to treat malaria during pregnancy in sub-Saharan Africa is scarce [9-12].”
BackgroundSelf-citationSaito, M., Gilder, M. E., Nosten, F. H., McGready, R. M., & Guerin, P. J. (2017) · Malaria Journal · doi:10.1186/s12936-017-2135-y · Cited by 35
“In one study, one-third of the recrudescence following AL or artesunate monotherapy occurred after day 42 [45], and four studies reported recrudescence after 100 days with a maximum of 138 days [42, 44, 48, 78].”
BackgroundInfluentialSelf-citationKloprogge, F., McGready, R. M., Hanpithakpong, W., Blessborn, D., Day, N., White, N. J., Nosten, F. H., & Tärning, J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00267-15 · Cited by 37
Self-citationKloprogge, F., McGready, R. M., Phyo, A. P., Rijken, M. J., Hanpithakpon, W., Than, H. H., Hlaing, N., Zin, N. T., Day, N., White, N. J., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12660 · Cited by 34
“pregnancy on the Thailand-Myanmar border [9].”
BackgroundSelf-citationChemotherapeutic Strategies for Reducing Transmission of Plasmodium vivax Malaria
Douglas, N. M., John, G. K., von Seidlein, L., Anstey, N. M., & Price, R. N. (2012) · Advances in Parasitology/Advances in parasitology · doi:10.1016/b978-0-12-397900-1.00005-0 · Cited by 35
Clark, R. L. (2011) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.22868 · Cited by 35
Kovacs, S., van Eijk, A. M., Sevene, E., Dellicour, S., Weiss, N. S., Emerson, S. S., Steketee, R. W., ter Kuile, F. O., & Stergachis, A. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164963 · Cited by 33
Artemether-Lumefantrine: An Option for Malaria
Stover, K. R., King, S. T., & Robinson, J. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q539 · Cited by 38
Kredo, T., Mauff, K. A. L., Workman, L., der Walt, J. S. V., Wiesner, L., Smith, P. J., Maartens, G., Cohen, K., & Barnes, K. I. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-016-1345-1 · Cited by 28
Pharmacovigilance of artemether-lumefantrine in pregnant women followed until delivery in Rwanda
Rulisa, S., Kaligirwa, N., Agaba, S., Karema, C., Mens, P. F., & de Vries, P. J. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-225 · Cited by 29
“Several studies have reported that Artemether and AL do not have teratogenic effects [17-20].”
BackgroundPharmacokinetics of Antimalarials in Pregnancy: A Systematic Review
Wilby, K. J., & Ensom, M. H. H. (2011) · Clinical Pharmacokinetics · doi:10.2165/11594550-000000000-00000 · Cited by 32
DJIMDÉ, A. A., Teketé, M., Abdulla, S., Lyimo, J., Bassat, Q., Mandomando, I., Lefèvre, G. Y., Borrmann, S., & for the B2303 Study Group (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01115-10 · Cited by 28
“However, the observed lower-than-average lumefantrine concentrations in the few patients with treatment failure who had pharmacokinetic sampling are in agreement with several reports from studies in Thailand and Papua New Guinea showing that the lumefantrine plasma level is a key determinant of A-L efficacy (8, 12, 16…”
ResultSaito, M., Gilder, M. E., Nosten, F. H., Guerin, P. J., & McGready, R. M. (2017) · Malaria Journal · doi:10.1186/s12936-017-2136-x · Cited by 29
“Six studies did not define the term but reported miscarriage [26, 31, 36, 41, 45, 74].”
MethodInfluentialSelf-citationOnyamboko, M. A., Hoglund, R. M., Lee, S. J., Kabedi, C., Kayembe, D. K., Badjanga, B. B., Turner, G. D. H., Jackson, N. V., Tärning, J., McGready, R. M., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01140-19 · Cited by 29
“Previous studies suggested that exposure to these drugs is reduced in pregnancy (5, 9, 11, 22, 23).”
BackgroundInfluentialSelf-citationBurger, R. J., van Eijk, A. M., Bussink, M., Hill, J., & ter Kuile, F. O. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv170 · Cited by 27
Efferth, T., Romero, M. R., Bilia, A. R., Osman, A. G., ElSohly, M. A., Wink, M., Bauer, R., Khan, I. A., Bergonzi, M. C., & Marín, J. J. G. (2016) · World Journal of Traditional Chinese Medicine · doi:10.15806/j.issn.2311-8571.2016.0002 · Cited by 29
Saito, M., Carrara, V. I., Gilder, M. E., Min, A. M., Tun, N. W., Pimanpanarak, M., Viladpai-nguen, J., Paw, M. K., Haohankhunnatham, W., Konghahong, K., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02002-8 · Cited by 25
Self-citationTinto, H., Sevene, E., Dellicour, S., Calip, G. S., D’Alessandro, U., Macete, E., Diallo, S. N., Kazienga, A., Valéa, I., Sorgho, H., et al. (2015) · Reproductive Health · doi:10.1186/s12978-015-0101-0 · Cited by 28
Mutagonda, R. F., Kamuhabwa, A. A. R., Minzi, O., Massawe, S. N., Maganda, B. A., & Aklillu, E. (2016) · Malaria Journal · doi:10.1186/s12936-016-1327-1 · Cited by 27
“The findings are in line with previous reports from Thailand where day 7 LF concentration above 600 ng/ml was associated with 100 % efficacy in pregnant women [14].”
BackgroundResultInfluentialFellmeth, G. L., Plugge, E., Carrara, V. I., Fazel, M. S., Oo, M., Phichitphadungtham, Y., Pimanpanarak, M., Wai, K., Mu, O., Charunwatthana, P., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-017129 · Cited by 27
Self-citationNovel anti-malarial combinations and their toxicity
Angus, B. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.907523 · Cited by 28
“(2008) AL Oral 125 2,3 Well-tolerated and safe [128]”
BackgroundMalaria prevention in the pregnant traveller: A review
Roggelin, L., & Cramer, J. P. (2014) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2014.04.007 · Cited by 29
Ballard, S.-B., Salinger, A., MPHc, Arguin, P. M., Desai, M., & Tan, K. R. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6714a4 · Cited by 24
“Low birth weight, 6/33 (18) Tinnitus, (66)§”
BackgroundDiagnostic and treatment difficulties of pyelonephritis in pregnancy in resource-limited settings.
McGready, R., Wuthiekanun, V., Ashley, E. A., Tan, S. O., Pimanpanarak, M., Viladpai-nguen, S. J., Jesadapanpong, W., Blacksell, S. D., Proux, S., Day, N. P., et al. (2010) · The American Society of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2010.10-0332 · Cited by 23
Self-citationCoartem®: a decade of patient-centric malaria management
Hamed, K. A., & Grueninger, H. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.51 · Cited by 26
Toure, O. A., Kone, P. L., Coulibaly, M., Ako, B., Gbessi, E. A., Coulibaly, B., N¿ Guessan, L. T., Koffi, D., Beourou, S., Soumahoro, A., et al. (2014) · Parasites & Vectors · doi:10.1186/preaccept-1316351532117712 · Cited by 21
“A low prevalence of peripheral and placental Plasmodium infection at delivery was also observed in Bangui, Central African Republic [27] and in Thailand [28].”
BackgroundLaochan, N., Zaloumis, S. G., Imwong, M., Lek-Uthai, U., Brockman, A., Sriprawat, K., Wiladphaingern, J., White, N. J., Nosten, F., & McGready, R. (2015) · Malaria Journal · doi:10.1186/s12936-015-0745-9 · Cited by 20
“In pregnancy, when a woman may naturally follow antenatal care for an extended period, much longer carriage times have been reported: 133 days in Malawi [14], 187 days in Mozambique [15], 85 days [7], 98 days [10] and 121 days [3] on the Thailand-Myanmar border.”
BackgroundSelf-citationNambozi, M., Kabuya, J.-B. B., Hachizovu, S., Mwakazanga, D. K., Mulenga, J., Kasongo, W., Buyze, J., Mulenga, M., Geertruyden, J. V., & D’Alessandro, U. (2017) · Malaria Journal · doi:10.1186/s12936-017-1851-7 · Cited by 21
“On the pregnancy outcomes, there was no significant difference between treatments for stillbirths, miscarriages, congenital malformations and prematurity, a finding similar to those of other studies on AL [22, 40, 41], mefloquine [5] and DHAPQ [42].”
ResultGeertruyden, J. V. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s4483 · Cited by 32
“A study that evaluated PK of AL in pregnant women with recrudescent uncomplicated multidrug resistant falciparum malaria demonstrated that pregnant women in second and third trimester had lower concentrations of artemether, dihydroartemisinin and lumefantrine, and elimination of lumefantrine was more rapid than report…”
Gray, A. M., Arguin, P. M., & Hamed, K. A. (2015) · Malaria Journal · doi:10.1186/s12936-015-0881-2 · Cited by 21
Prevention and Treatment of Malaria in Pregnancy
Davis, T. M. E., Müeller, I., & Rogerson, S. J. (2010) · Future Microbiology · doi:10.2217/fmb.10.113 · Cited by 19
Das, J. L., Rulisa, S., de Vries, P. J., Mens, P. F., Kaligirwa, N., Agaba, S., Tärning, J., Karlsson, M. O., & Dorlo, T. P. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00518-18 · Cited by 22
Malaria in Pregnancy: Update on Emergency Management
Smereck, J. (2011) · The Journal of Emergency Medicine · doi:10.1016/j.jemermed.2010.04.029 · Cited by 18
“Coartem (Novartis, Basel, Switzerland), a drug composed of both artemether and lumefantrine, was approved by the US Food and Drug Administration in 2009 for the treatment of acute, uncomplicated malaria infections for adults and children who weigh over 5 kilograms (42,43).”
BackgroundBurger, R. J., Visser, B. J., Grobusch, M. P., & van Vugt, M. (2016) · Malaria Journal · doi:10.1186/s12936-016-1160-6 · Cited by 18
“Lumefantrine The pharmacokinetic properties of lumefantrine were investigated in six studies [18, 19, 35, 37, 49, 61].”
BackgroundMethodInfluentialLi, Q., Si, Y., Xie, L. H., Zhang, J., & Weina, P. J. (2009) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20207 · Cited by 17
Shibeshi, W., Baye, A. M., Alemkere, G., & Engidawork, E. (2021) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s336771 · Cited by 19
“Among the documented mean or median body weights, participants from Sudan(28) and Nigeria(23,24,44) had the highest body weight compared with those from Thailand.(15,40) Detailed description of study participants included in this systematic review and meta-analysis is indicated in a supplementary file (S3 Table).”
BackgroundMethodResultInfluentialAdegbola, A. J., Abutaima, R., Olagunju, A., Ijarotimi, O. A., Siccardi, M., Owen, A., Soyinka, J. O., & Bolaji, O. O. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01252-18 · Cited by 14
Kwansa‐Bentum, B., Ayi, I., Suzuki, T., Otchere, J., Kumagai, T., Anyan, W. K., Asahi, H., Akao, N., Wilson, M. D., Boakye, D. A., et al. (2011) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2011.02833.x · Cited by 16
“This may be due to the lack of conclusive research about the safety of artemisinin derivatives on pregnancy, particularly in the early weeks (McGready et al. 2001; McGready et al. 2008 Dellicour et al. 2007).”
BackgroundPadberg, S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-408078-2.00007-x · Cited by 19
Safety, Pharmacokinetics and Efficacy of Artemisinins in Pregnancy
Ades, V. (2011) · Infectious Disease Reports · doi:10.4081/idr.2011.2412 · Cited by 14
Manirakiza, A., Serdouma, E., Djallé, D., Soula, G., Laganier, R., Madji, N., Moyen, J. M., Faou, A. L., & Delmont, J. P. (2011) · Journal of Tropical Medicine · doi:10.1155/2011/434816 · Cited by 15
“8%, respectively [17].”
Optimizing Therapeutic Drug Monitoring in Pregnant Women: A Critical Literature Review
Moreira, F. D. L., Benzi, J. R. D. L., Pinto, L., Thomaz, M. D. L., Duarte, G. G., & Lanchote, V. L. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001039 · Cited by 14
Drug-induced hypersensitivity to artemisinin-based therapies for malaria
Nordmann, T., Borrmann, S., & Ramharter, M. (2021) · Trends in Parasitology · doi:10.1016/j.pt.2021.08.011 · Cited by 14
No Association of Phenotypic ABO Blood Group and Malaria during Pregnancy
Boel, M. E., Rijken, M. J., Pimanpanarak, M., Keereecharoen, N. L., Proux, S., Nosten, F., & McGready, R. (2012) · The American Society of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2012.12-0129 · Cited by 11
Self-citationUse of artemether–lumefantrine to treat malaria during pregnancy: what do we know and need to know?
Mutabingwa, T. K., & Adam, I. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.169 · Cited by 14
Expanding the Use of Primaquine for the Radical Cure of Plasmodium vivax
Price, R. N., & Douglas, N. M. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy236 · Cited by 11
“Malaria treatment guidelines derived by such means have resulted in underdosing of sulfadoxine-pyrimethamine in children [9], of artemether-lume-fantrine in pregnant women [10], and of dihydroartemisinin-piper-aquine in low-weight children [11].”
BackgroundMcCarthy, J. S., & Price, R. N. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00040-0 · Cited by 14
Teratogen update: Malaria in pregnancy and the use of antimalarial drugs in the first trimester
Clark, R. L. (2020) · Birth Defects Research · doi:10.1002/bdr2.1798 · Cited by 12
“Another treatment regimen that has been tested is artesunate monotherapy using 2 mg/kg/day for 7 days (e.g., McGready et al., 2008).”
BackgroundMethodResultInfluentialSaito, M., Yotyingaphiram, W., Cargill, Z., Gilder, M. E., Min, A. M., Phyo, A. P., San, T. D., Poe, H., Chu, C. S., White, N. J., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02473-20 · Cited by 10
Self-citationCarmona‐Fonseca, J., Agudelo-Garcia, O. M., & Arango, E. (2013) · Revista Colombiana de Obstetricia y Ginecología · doi:10.18597/rcog.127 · Cited by 12
“El tratamiento estándar de seis dosis de AM-LF es eficaz y bien tolerado en otros lugares, donde su eficacia, sin embargo, fue inferior a la mostrada por la monoterapia con artesunato oral por 7 días (32).”
BackgroundMarcel, U., Badejoko, O. O., Ogunniyi, S. O., Loto, O. M., Aboderin, O., & Fatusi, A. O. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2015.05.009 · Cited by 10
“The median reported intervals to symptomatic relief of approximately 2 days in both the artesunate-amodiaquine and artemetherlumefantrine groups of the present study are also similar to the findings of other investigators [12–14].”
ResultTreatment regimens for pregnant women with falciparum malaria
Moore, B. R., Salman, S., & Davis, T. M. E. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2016.1202758 · Cited by 11
“[27,30,58,61,75] that may relate to pregnancy-associated physiologic changes including a lower bioavailability and increased metabolism [61].”
BackgroundArtemisinin and its derivatives: a potential therapeutic approach for oral lichen planus
Ma, R., He, M., Tan, Y., & Zhou, G. (2019) · Inflammation Research · doi:10.1007/s00011-019-01216-0 · Cited by 9
Clark, R. L. (2022) · Reproductive Toxicology · doi:10.1016/j.reprotox.2022.05.016 · Cited by 10
Time-to-infection by Plasmodium falciparum is largely determined by random factors
Pinkevych, M., Chelimo, K., VULULE, J. M., Kazura, J. W., Moormann, A. M., & Davenport, M. P. (2015) · BMC Medicine · doi:10.1186/s12916-014-0252-9 · Cited by 8
“The constant τ = 7 days is the first day blood-stage infection could be initiated after treatment due to the pharmacodynamics of lumefantrine [12,16-22], λ is the rate of initiation of the blood-stage infection.”
BackgroundLefèvre, G. Y., Marrast, A. C., & Grueninger, H. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05973.x · Cited by 8
Which drug is effective and safe for acute malaria in pregnancy? Reviewing the evidence
McGready, R. M., & Nosten, F. H. (2009) · Drug Development Research · doi:10.1002/ddr.20348 · Cited by 9
“This evidence has been further verified in pregnancy with PCR genotyping data in a recently published trial of artemisinin-based combination therapy [McGready et al., 2008].”
BackgroundMethodSelf-citationDalrymple, D. G. (2010) · Cited by 9
Elbadawi, N. E. E., Mohamed, M. I., Dawod, O. Y., Ali, K. E., Daoud, O. H., Ali, E. M., Ahmed, E. G. E., & Mohamed, A. E. (2011) · Eastern Mediterranean Health Journal · doi:10.26719/2011.17.9.697 · Cited by 7
Metadata
- Authors
- McGready, R., Tan, S. O., Ashley, E. A., Pimanpanarak, M., Viladpai-nguen, J., Phaiphun, L., Wüstefeld, K., Barends, M., Laochan, N., Keereecharoen, L., Lindegardh, N., Singhasivanon, P., White, N. J., & Nosten, F.
- Affiliations
- Mahidol University (TH)
- Shoklo Malaria Research Unit (TH)
- Corresponding author
- McGready, Rose
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-23
- Volume
- 5
- Issue
- 12
- Pages
- e253
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2605900
- OpenAlex
- W2008309617
- Cited by
- 136
- References
- 45
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 6 · 2020: 6 · 2019: 5 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 13 · 2014: 14 · 2013: 9 · 2012: 13
- FWCI
- 12.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Greater South Information System
- Funders
- Wellcome Trust
- Mahidol University
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- artemether-lumefantrine, falciparum malaria, malaria in pregnancy, uncomplicated malaria, artemisinin-based combination therapy, cure rate, relapse, pharmacokinetics, lumefantrine, Karen women, birth outcomes, infant outcomes, safety and tolerability, northwestern Thailand
- MeSH terms
- Artesunate, Artemether, Lumefantrine, Adult, Animals, Antimalarials, Drug Therapy, Combination, Ethanolamines, Female, Fluorenes, Humans, Infant, Infant, Newborn, Plasmodium falciparum, Pregnancy, Thailand, Pregnancy Complications, Parasitic, Malaria, Falciparum, Parasitic Sensitivity Tests, Artemisinins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.